YMN-136 Vaccine for Patients With Liver Metastasis of Colorectal Cancer Progressing After Third-Line Treatment

Inclusion criteria

• . Voluntarily sign the informed consent form, be able to understand and agree to follow the prescribed research procedures and visits;
• . Aged 18-75 years, both male and female are eligible;
• . Histologically confirmed unresectable advanced colorectal adenocarcinoma;
• . Patients with colorectal cancer liver metastasis who have failed third-line treatment, defined as those who have experienced disease progression (based on RECIST 1.1 criteria) or terminated treatment due to intolerance to toxicity after completing at least three different treatment regimens in the standard sequence during systemic treatment for colorectal cancer. The specific treatment pathway usually includes:
• . Eastern Cooperative Oncology Group (ECOG) physical status score: 0 or 1;
• . Expected survival ≥12 weeks;
• . During the screening period, the organ function levels must meet the following requirements:
• . Qualified patients (males or females) with reproductive capacity must agree to use a medically approved physical contraceptive method (such as intrauterine device, condom, tubal or vasectomy ligation, etc.) during the trial period and within 6 months after the last dose; female patients of childbearing age must have negative serum or urine HCG test results during the screening period.

Exclusion criteria